Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 3/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10459207 | 0.83 | CYP1A2 (0.69) | CYP1A2CYP2D6ALDH1A1MGLLGAA | |
| SCHEMBL25259084 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL29082797 | 0.82 | GAA (0.55) | CYP1A2CYP2D6ALDH1A1MGLLFAAH | |
| SCHEMBL25261019 | 0.82 | CYP1A2 (0.60) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL18986983 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25299888 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL2105035 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL14236800 | 0.78 | RAB9A (0.63) | ALDH1A1KMT2ARAB9AGAA | |
| SCHEMBL25303194 | 0.78 | CYP1A2 (0.53) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL25303037 | 0.78 | CYP1A2 (0.53) | CYP1A2CYP2D6MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| WO-2018038265-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | CYP1A2 917/4885CYP2D6 1148/4885ALDH1A1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.